Mark J. Ratain to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Mark J. Ratain has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.181
-
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
Score: 0.112
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.069